| Literature DB >> 32824374 |
Veronika Vozáriková1, Nina Kunová2, Jacob A Bauer2, Ján Frankovský1, Veronika Kotrasová2, Katarína Procházková1, Vladimíra Džugasová1, Eva Kutejová2, Vladimír Pevala2, Jozef Nosek3, Ľubomír Tomáška1.
Abstract
Mitochondrial DNA (mtDNA) molecules are packaged into compact nucleo-protein structures called mitochondrial nucleoids (mt-nucleoids). Their compaction is mediated in part by high-mobility group (HMG)-box containing proteins (mtHMG proteins), whose additional roles include the protection of mtDNA against damage, the regulation of gene expression and the segregation of mtDNA into daughter organelles. The molecular mechanisms underlying these functions have been identified through extensive biochemical, genetic, and structural studies, particularly on yeast (Abf2) and mammalian mitochondrial transcription factor A (TFAM) mtHMG proteins. The aim of this paper is to provide a comprehensive overview of the biochemical properties of mtHMG proteins, the structural basis of their interaction with DNA, their roles in various mtDNA transactions, and the evolutionary trajectories leading to their rapid diversification. We also describe how defects in the maintenance of mtDNA in cells with dysfunctional mtHMG proteins lead to different pathologies at the cellular and organismal level.Entities:
Keywords: Abf2; DNA-binding; HMG-box protein; TFAM; mitochondria; mitochondrial disease; mitochondrial nucleoid
Mesh:
Substances:
Year: 2020 PMID: 32824374 PMCID: PMC7463775 DOI: 10.3390/biom10081193
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1The domain organization of yeast (Abf2) and human (mitochondrial transcription factor A (TFAM)) HMG-box containing proteins (mtHMG) proteins. The amino-acid sequences of the two HMG-box domains of Abf2 (from S. cerevisiae, S. uvarum, Candida glabrata, Naumovozyma castellii, N. dairenensis, and Vanderwaltozyma polyspora) and TFAM (from human, mouse, rat, Xenopus laevis, and Drosophila melanogaster) were predicted using Simple Modular Architecture Research Tool (SMART) [148] and aligned using multiple sequence alignment software MAFFT (multiple alignment using fast Fourier transform) v7.450 [149]. The sequence logos were created using Geneious v11.1.5 (Biomatters). The mitochondrial targeting sequences (MTS) are based on experimental evidence [58,76].
Figure 2Visualization of DNA in wild-type cells vs. mutants lacking mtHMG protein (ΔmtHMG). Nuclear DNA (large blue dots) and mt-nucleoids (smaller blue spots) were visualized in yeast cells using confocal microscopy (Olympus IX81) after DAPI staining. As in the S. cerevisiae abf2− mutant, the deletion of mtHMG genes in Y. lipolytica, a strictly aerobic yeast, resulted in a decreased number of mt-nucleoids.
Figure 3Structures of Abf2 and TFAM in complex with DNA. (a) Abf2 in complex with DNA (PDB ID 5JH0; [201]); HMG-box 1 is colored blue, HMG-box 2 is colored green. The two separate DNA molecules are colored differently to differentiate them. The pink α-helices are the additional N-terminal α-helices known so far only from Abf2. (b) TFAM in complex with DNA (PDB ID 3TMM; [207]); HMG-box 1 is colored blue, HMG-box 2 is colored green, the 30-residue linking helix is colored magenta. The N-terminal extension is pink.
Figure 4Possible means of regulating mtHMG proteins. The levels of mtHMG proteins can be controlled at the level of transcription by employing specific transcription factors (TFs) as well as by epigenetic markers such as DNA methylation. In the case of TFAM, alternative splicing generates isoforms differing in the number of functional HMG-boxes. Prior to or following their import into mitochondria, mtHMG proteins can undergo various post-translational modifications (PTMs) that can affect their susceptibility to proteolytic degradation, propensity to interact with protein partners (not shown), and DNA-binding activity. As a result, mitochondrial DNA (mtDNA) can be either tightly compacted or more relaxed and thus more accessible to the components of the replication, transcription, recombination, and translation machineries. See text for more details.
Examples of human diseases whose pathologies involve TFAM.
| Disease | Model | Variant | mRNA | Protein | mtDNA | Ref. |
|---|---|---|---|---|---|---|
| Mitochondrial DNA depletion syndrome 15 | patient | +/+ Pro178Leu | ↑ | ↓ | ↓ copies | [ |
| Extrahepatic cholestasis | cell line | gene disruption | ↓ | (↑)↓ | ↓ copies | [ |
| Cardiomyopathy | mouse | KO in germline | ↓ | ↓ | ↓copy in +/−depletion | [ |
| Cardiomyopathy | mouse | KO | – | ↓ | ↓ transcripts | [ |
| Myopathy | mouse | KO | – | ↓ | ↓ copies | [ |
| Infantile mitochondrial myopathy | cell line | – | ↑ 1 | depletion 1,3 | [ | |
| Carotid artery injury | rat | KD | ↑after injury | ↑ | ↑ mass | [ |
| Chronic obstructive pulmonary disease | cell line | hyper-methylation of promoter | ↓ | ↓ | – | [ |
| Gastric cancer | cell line | KD | ↓ | ↓ | ↓ copies | [ |
| Colorectal cancer with microsatellite instability | cell line | Leu149Stop frameshift | – | ↓ | ↓ copies | [ |
| Colon cancer | mouse | KO | – | ↓ | depletion | [ |
| Colon cancer | cell line | ↑ | ↑ | ↑ | – | [ |
| Colon cancer | cell line | ↓ | ↑ | ↑ | – | [ |
| Epidermoid cancer/ | cell line | chemo-therapeutics treatment | ↓↑ | ↓↑ | – | [ |
| Bladder cancer | cell line | ↓ | – | ↑ | – | [ |
| Clear cell renal cell carcinoma | cell line | KD 1 | ↓ 1 | ↓ 1 | ↓ copies | [ |
| Clear cell renal cell carcinoma | cell line | OE SIRT3 | ↑ | ↑ | ↑biogenesis | [ |
| Non-small cell lung cancer | cell line | KD 1 | ↓ 1 | ↓ 1 | ↓ copies 1 | [ |
| Lung adenocarcinoma/ | cell line | – | ↑in lactic acidosis | – | ↑ copies | [ |
| Lung adenocarcinoma | cell line | KD, | – | ↑ | ↑ copies | [ |
| Lung adenocarcinoma | cell line | – | – | ↓ 1 | ↓ biogenesis | [ |
| Glioma | cell line | ↓ | ↑ | ↑ | – | [ |
| Glioma | cell line | interaction with KLF16 | ↓ | ↓ | – | [ |
| Glioma | cell line | melatonin treatment | ↓ | ↓ | ↓ transcripts | [ |
| Diffusely infiltrating astrocytoma (a type of glioma) | patient | – | ↑ | – | ↓ copies | [ |
| Arsenic-induced Bowen’s disease | cell line | arsenic exposure 1,3 | ↑ | ↑ | ↑ copies | [ |
| Melanoma | cell line | – | ↓↑ | – | mutations | [ |
| Prostate cancer | cell line | – | ↑ | ↑ | mtDNA point mutation | [ |
| Cervical cancer | cell line | miRNA-214 | ↓ | ↓ | – | [ |
| Ovarian cancer | patient | – | – | ↑ | – | [ |
| Endometrial cancer | patient | – | – | ↑ | ↑ copies | [ |
| Breast cancer (estrogen-positive type) | cell line | KD 1 | ↑ 3 | ↑ 3 | – | [ |
| Hepatocellular carcinoma | patient | – | – | ↑ | ↓ copies | [ |
| Esophageal squamous cell carcinoma | cell line | KD 1 | – | ↓ 1 | ↑ copies 3 | [ |
| Esophageal squamous cell carcinoma | cell line | KD 1 | ↓ 1 | ↓ 1 | ↓ copy | [ |
↑: Increase; ↓: Decrease; +/+: Homozygous; +/−: Heterozygous; 1: Cell line; 2: Mouse; 3: Patient; KO: Knockout; KD: Knockdown; OE: Overexpression; see Table S1 for more details.